# A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05951608/  
OnCo record `nct05951608` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AK127 in combination with AK112 in advanced solid tumours, run by Akeso, active and no longer recruiting.

## Summary

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05951608 by Akeso, with 216 participants enrolled, started 2023-10-16 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK127 in combination with AK112.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05951608
- Phase: 1/2
- Setting: A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK112 in Patients With Advanced Malignant Tumors
- Sponsor: Akeso
- Enrolled: 216

## Sources

- ClinicalTrials.gov NCT05951608: https://clinicaltrials.gov/study/NCT05951608

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05951608.json